<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03313544</url>
  </required_header>
  <id_info>
    <org_study_id>2017-01</org_study_id>
    <secondary_id>2017-001197-42</secondary_id>
    <nct_id>NCT03313544</nct_id>
  </id_info>
  <brief_title>Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1</brief_title>
  <official_title>Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting Programmed Cell Death 1 (PD-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, monocentric clinical study. Patients selected for nivolumab therapy in AP-HM for
      melanoma and non-small cell lung cancer will be eligible. Do not include patients with
      conditions that do not allow MRI, prior cardiovascular disease with LVEF&lt;50%, cardiomyopathy,
      history of cardiac arrhythmia, history of cardiovascular toxicity under anticancer therapy,
      coronary artery disease or stroke less than 3 months Therapeutic management will not be
      modified and treatment will be administrated as usual.

      Cardiovascular follow up will be identical to that recommended and realized in current care
      in the Cardio-Oncology unit of AP-HM. It will include clinical, biological (BNP and troponin)
      and trans-thoracic echocardiography (TTE) at baseline and then at 1, 3 and 6 months.
      Auto-antibodies against troponin I assay will be performed to avoid false negatives of normal
      blood level of troponin I at baseline and then at 6 months. Cardiac MRI will be performed as
      well at baseline and at the end of the study (6 months). MRI is the gold standard for
      ventricular function evaluation.

      Primary endpoint will be left ventricular function evolution evaluated by global longitudinal
      strain (GLS, 2D speckles tracking) in TTE. Secondary endpoints will be left and right
      ventricular function parameters: LEVF by TTE and MRI, left ventricular indexed volumes by TTE
      and MRI, right ejection ventricular function and indexed volumes by TTE and MRI, systolic
      pulmonary arterial pressure by TTE, serum troponin I and BNP, arrhythmias and conduction
      disorders on the electrocardiogram (ECG).

      Number of required subjects: GLS is recommended for following up left ventricular function
      under anticancer treatments. Based on the hypothesis of a significant GLS decrease (15%) in
      20% of cases with alpha risk of 0.05 and accuracy of 0.12 which means expected confidence
      interval of 0.08-0.32, then the number of required subjects is 50 patients.

      The inclusion period will be 18 months with a follow up if 6 months, ie a total duration of
      the study of 24 months.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2017</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>systolic pulmonary arterial pressure</measure>
    <time_frame>6 months</time_frame>
    <description>trans-thoracic echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ventricular function evaluation.</measure>
    <time_frame>6 MONTHS</time_frame>
    <description>MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum troponin I</measure>
    <time_frame>1,3, 6 months</time_frame>
    <description>BLOOD SAMPLES</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain natriuretic peptide (BNP)</measure>
    <time_frame>1,3, 6 months</time_frame>
    <description>BLOOD SAMPLES</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Melanoma</condition>
  <condition>Non-small Cell</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>NIVOLUMAB PATIENTS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>NIVOLUMAB</description>
    <arm_group_label>NIVOLUMAB PATIENTS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Cardiac MRI 6 MONTHS</description>
    <arm_group_label>NIVOLUMAB PATIENTS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BLOOD SAMPLES</intervention_name>
    <description>biological (BNP and troponin)</description>
    <arm_group_label>NIVOLUMAB PATIENTS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>trans-thoracic echocardiography</intervention_name>
    <description>1, 3 and 6 months</description>
    <arm_group_label>NIVOLUMAB PATIENTS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        patients treated with nivolumab

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Preliminary cardiac disease with FeVG &lt;50%

          -  Cardiomyopathy dilated, hypertrophic or restrictive

          -  History of cardiac arrhythmia

          -  History of cardiac toxicity under another anti-cancer treatment

          -  Known coronary disease

          -  History of stroke less than 3 months old

          -  Patient not wishing to participate in the study

          -  Vulnerable persons (pregnant women, adults under guardianship or guardianship, persons
             deprived of their liberty)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Olivier ARNAUD</last_name>
    <role>Study Director</role>
    <affiliation>assistance publique h√¥pitaux de marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>jennifer CAUTELA</last_name>
    <phone>0491968289</phone>
    <email>jennifer.cautela@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ALEXANDRA GIULIANI</last_name>
    <phone>0491382747</phone>
    <email>drci@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>JENNIFER CAUTELA</last_name>
      <email>jennifer.cautela@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>jennifer CAUTELA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>October 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2017</study_first_posted>
  <last_update_submitted>October 13, 2017</last_update_submitted>
  <last_update_submitted_qc>October 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

